

DESCRIPTION

Source *E. coli*-derived
His29-Ser209, with a N-terminal 5-His tag
Accession # Q9NSA1

N-terminal Sequence Analysis His

Predicted Molecular Mass 20.2 kDa

SPECIFICATIONS

SDS-PAGE 24 kDa, reducing conditions

Activity Measured in a cell proliferation assay using BaF3 mouse pro-B cells transfected with human FGF RIIIc. The ED₅₀ for this effect is typically 0.06-0.4 µg/mL in the presence of Recombinant Mouse Klotho β (Catalog # 2619-KB).

Endotoxin Level <0.01 EU per 1 µg of the protein by the LAL method.

Purity >97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Lyophilized from a 0.2 µm filtered solution in MES, Na₂SO₄, EDTA and DTT with BSA as a carrier protein. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 100 µg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.


Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.


DATA

Bioactivity



Recombinant Human FGF-21 (Catalog # 2539-FG) stimulates cell proliferation of the BaF3 mouse pro-B cell line transfected with human FGF RIIIc. The ED₅₀ for this effect is typically 0.06-0.4 µg/mL in the presence of Recombinant Mouse Klotho β (Catalog # 2619-KB).

SDS-PAGE



1 µg/lane of Recombinant Human FGF-21 was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 24 kDa.

BACKGROUND

Fibroblast growth factor 21 (FGF-21) is a member of the FGF gene family, which currently contains 22 human members. Based on its structure, it is further classified as an FGF19 subfamily member. This subfamily includes FGF-19, -21, and -23. Like all other FGF subfamilies, FGF-19 subfamily members contain a 120 amino acid (aa) core FGF domain that exhibits a β -trefoil structure (1, 2). Unlike other FGF subfamilies, FGF-19 subfamily members apparently exhibit poor binding to ECM, resulting in highly diffusible molecules (3). The c-DNA for FGF-21 predicts a 209 aa polypeptide that contains a 28 aa signal sequence and a 181 aa mature region (4). Notably, FGF-21, as well as FGF-19 show limited binding to heparin (4). One potential alternate splice form has been reported. It shows a 43 aa substitution for the C-terminal 12 aa of the standard form (5). Mature human FGF-21 shows 81% aa identity to mouse FGF-21, and is known to be active on mouse cells (4, 6). The FGF-19 subfamily is considered endocrine in nature. All three subfamily members impact some aspect of metabolism, all three are induced by a nuclear receptor heterodimer that includes RXR, and all three utilize Klotho family members for signal transduction (7, 8, 9). FGF-21 is produced by hepatocytes in response to free fatty acid (FFA) stimulation of a PPAR α /RXR dimeric complex (3, 7, 10, 11). This situation occurs clinically during starvation, or following the ingestion of a high-fat/low-carbohydrate diet. Upon FGF-21 secretion, white adipose tissue is induced to release FFAs from triglyceride stores. Once FFAs reach hepatocytes, they are oxidized and reduced to acetyl-CoA. The acetyl-CoA is recombined into 4-carbon ketone bodies (acetoacetate and β -hydroxybutyrate), released, and transported to peripheral tissues for TCA processing and energy generation (11, 12).

References:

1. Itoh, N. and D.M. Ornitz (2004) Trends Genet. **20**:563.
2. Mohammadi, M. *et al.* (2005) Cytokine Growth Factor Rev. **16**:107.
3. Huang, X. *et al.* (2006) Mol. Carcinog. **45**:934.
4. Nishimura, T. *et al.* (2000) Biochim. Biophys. Acta **1492**:203.
5. GenBank Accession #: EAW52401 (2006).
6. Ford, A.M. *et al.* (2005) J. Clin. Invest. **115**:1627.
7. Moore, D. D. (2007) Science **316**:1436.
8. Ogawa, Y. *et al.* (2007) Proc. Natl. Acad. Sci. USA **104**:7432.
9. Kurosu, H. *et al.* (2007) J. Biol. Chem. **282**:26687.
10. Lundasen, T. *et al.* (2007) Biochem. Biophys. Res. Commun. **360**:437.
11. Badman, M.K. *et al.* (2007) Cell Metab. **5**:426.
12. Inagaki, T. *et al.* (2007) Cell Metab. **5**:415.